Home » Regions » Global News » AB-Biotics, Scienta Farma partner to sell pharmacogenetic test in Mexico

AB-Biotics, Scienta Farma partner to sell pharmacogenetic test in Mexico

Wednesday, October 2, 2013

Spanish biotech company AB-Biotics and Scienta Farma reached an agreement to sell the pharmacogenetic test Neurofarmagen in Mexico. This test, developed by AB-Biotics, identifies the most optimum medication for each individual patient with depression, schizophrenia, bipolar disorder or epilepsy by analyzing DNA, extracted from a saliva sample.

Scienta Farma will have exclusive rights to distribute Neurofarmagen in Mexico. Mexico is the third country to launch Neurofarmagen. The test already is sold in Spain, marketed by Almirall, and in Brazil through GlaxoSmithKline. Over 33 million people suffer from mental disorder in Mexico, according to National Comorbidity Survey, and 60% (13.3 million patients) are being treated.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!